Although LRP6 is expressed in normal tissue, attenuated CDV-OP could act as an attractive choice for oncolytic virotherapy, as cancer cell-specificity may also be controlled by defective interferon signaling, which is often found to be the case in cancer cells (72). The gene discussed is LRP6; the disease is cancer.